Biomerica, Inc. (BMRA): Price and Financial Metrics


Biomerica, Inc. (BMRA): $3.06

0.24 (+8.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BMRA POWR Grades


  • Growth is the dimension where BMRA ranks best; there it ranks ahead of 87.39% of US stocks.
  • BMRA's strongest trending metric is Quality; it's been moving up over the last 170 days.
  • BMRA's current lowest rank is in the Momentum metric (where it is better than 7.43% of US stocks).

BMRA Stock Summary

  • BMRA has a market capitalization of $55,263,273 -- more than approximately only 9.8% of US stocks.
  • The ratio of debt to operating expenses for Biomerica Inc is higher than it is for about merely 17.58% of US stocks.
  • As for revenue growth, note that BMRA's revenue has grown 65.02% over the past 12 months; that beats the revenue growth of 86.42% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Biomerica Inc, a group of peers worth examining would be STXS, VRNS, BOX, FROG, and FIVN.
  • Visit BMRA's SEC page to see the company's official filings. To visit the company's web site, go to www.biomerica.com.

BMRA Valuation Summary

  • BMRA's price/sales ratio is 7.8; this is 105.26% higher than that of the median Healthcare stock.
  • Over the past 61 months, BMRA's EV/EBIT ratio has gone up 19.9.
  • BMRA's price/earnings ratio has moved up 7.5 over the prior 61 months.

Below are key valuation metrics over time for BMRA.

Stock Date P/S P/B P/E EV/EBIT
BMRA 2021-08-31 7.8 6.1 -8.7 -8.2
BMRA 2021-08-30 7.6 5.9 -8.4 -8.0
BMRA 2021-08-27 7.4 5.8 -8.2 -7.8
BMRA 2021-08-26 5.9 4.9 -9.6 -8.9
BMRA 2021-08-25 5.9 5.0 -9.6 -8.9
BMRA 2021-08-24 5.9 4.9 -9.5 -8.8

BMRA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BMRA has a Quality Grade of D, ranking ahead of 11.64% of graded US stocks.
  • BMRA's asset turnover comes in at 0.519 -- ranking 90th of 186 Medical Equipment stocks.
  • FONR, ECIA, and SMLR are the stocks whose asset turnover ratios are most correlated with BMRA.

The table below shows BMRA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-05-31 0.519 0.051 -0.937
2021-05-31 0.519 0.069 -0.813
2021-02-28 0.582 0.140 -0.660
2020-11-30 0.460 0.232 -0.584
2020-08-31 0.549 0.240 -0.493
2020-05-31 0.682 0.266 -0.357

BMRA Price Target

For more insight on analysts targets of BMRA, see our BMRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.00 Average Broker Recommendation 1 (Strong Buy)

BMRA Stock Price Chart Interactive Chart >

Price chart for BMRA

BMRA Price/Volume Stats

Current price $3.06 52-week high $7.38
Prev. close $2.82 52-week low $2.65
Day low $2.93 Volume 22,261
Day high $3.08 Avg. volume 57,102
50-day MA $3.90 Dividend yield N/A
200-day MA $4.36 Market Cap 39.33M

Biomerica, Inc. (BMRA) Company Bio


Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.


BMRA Latest News Stream


Event/Time News Detail
Loading, please wait...

BMRA Latest Social Stream


Loading social stream, please wait...

View Full BMRA Social Stream

Latest BMRA News From Around the Web

Below are the latest news stories about Biomerica Inc that investors may wish to consider to help them evaluate BMRA as an investment opportunity.

Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Coherus Biosciences (CHRS – Research Report) and Biomerica (BMRA – Research Report) with bullish sentiments. Coherus Biosciences (CHRS) In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Coherus Biosciences, with a price target of $30.00. The company's shares closed last Tuesday at $12.52, close to its 52-week low of $11.13. According to TipRanks.

Howard Kim on TipRanks | February 8, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning!

William White on InvestorPlace | February 8, 2022

Biomerica Posts Encouraging Results From InFoods Study As Irritable Bowel Syndrome Treatment

Biomerica Inc (NASDAQ: BMRA ) has announced topline results from its InFoods IBS diagnostic-guided therapy (DGT) endpoint clinical trial. The trial showed statistically significant improvements in multiple endpoints in the Intent-to-Treat population. The InFoods DGT uses a simple blood test to identify patient-specific foods that may alleviate Irritable Bowel Syndrome (IBS) symptoms such as pain, bloating, diarrhea, and constipation when removed from the … Full story available on Benzinga.com

Benzinga | February 8, 2022

Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS without the use of drugsMultiple endpoints demonstrated statistically significant improvements, indicating that the elimination of specific foods may meaningfully reduce the symptoms of IBS in all subtypes (clinical study included patients with IBS-Constipation, IBS-Diarrhea & IBS-Mixed) Greatest clin

Yahoo | February 8, 2022

Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021

Revenues up 239% over prior year fiscal second quarter Customer orders backlog of over $4.0 million at November 30, 2021 Walmart began in-store and online sales of Biomerica’s EZ Detect™ Colon Disease Test during fiscal second quarter InFoods® IBS endpoint trial is complete, topline trial results expected by the end of January IRVINE, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its second

Yahoo | January 13, 2022

Read More 'BMRA' Stories Here

BMRA Price Returns

1-mo N/A
3-mo -29.98%
6-mo -35.71%
1-year -10.79%
3-year 29.11%
5-year 14.18%
YTD -21.34%
2021 -21.89%
2020 64.68%
2019 77.88%
2018 -54.55%
2017 62.61%

Continue Researching BMRA

Here are a few links from around the web to help you further your research on Biomerica Inc's stock as an investment opportunity:

Biomerica Inc (BMRA) Stock Price | Nasdaq
Biomerica Inc (BMRA) Stock Quote, History and News - Yahoo Finance
Biomerica Inc (BMRA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7591 seconds.